Yusheng Han Buys 111,110 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 111,110 shares of the stock in a transaction on Tuesday, June 16th. The shares were purchased at an average cost of $9.00 per share, with a total value of $999,990.00. Following the transaction, the director directly owned 18,018,546 shares of the company’s stock, valued at approximately $162,166,914. This trade represents a 0.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.45 per share, with a total value of $779,642.50.
• On Friday, June 12th, Yusheng Han purchased 210,000 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of BNR opened at $9.82 on Friday. The stock has a market cap of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. Burning Rock Biotech Limited Sponsored ADR has a fifty-two week low of $3.23 and a fifty-two week high of $41.72. The firm’s 50-day simple moving average is $12.35 and its two-hundred day simple moving average is $19.96.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The business had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million.

Analysts Set New Price Targets

BNR has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

A number of institutional investors have recently made changes to their positions in BNR. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech during the fourth quarter valued at approximately $220,000. Prospera Financial Services Inc lifted its position in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after acquiring an additional 6,430 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Crcm LP boosted its stake in Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.